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The purpose of this open-labeled prospective study was to
compare the treatment effects of cyclical etidronate and
alendronate on the lumbar bone mineral density (BMD), bone
resorption, and back pain in elderly women with osteoporosis.
Fifty postmenopausal women with osteoporosis, age ranging
from 55 to 86 years (mean: 70.7 years), were randomly divided
into two groups with 25 patients in each group: the cyclical
etidronate group (etidronate 200 mg daily for 2 weeks every
3 months) and the alendronate group (5 mg daily). The BMD
of the lumbar spine (L1-L4) measured by DXA, the urinary
cross-linked N-terminal telopeptides of type I collagen (NTX)
level measured by the enzyme-linked immunosorbent assay,
and back pain evaluated by the face scale score were assessed
at baseline, 6 months, and 12 months. There were no signifi-
cant differences in baseline characteristics including age, body
mass index, years since menopause, lumbar BMD, urinary
NTX level, and face scale score between the two treatment
groups. Etidronate treatment sustained the lumbar BMD fol-
lowing a reduction in the urinary NTX level and improved
back pain, while alendronate treatment reduced the urinary
NTX level more significantly, resulting in an increase in the
lumbar BMD, and similarly improved back pain. No serious
adverse events were observed in either group. This study
confirmed that alendronate treatment had a greater efficacy
than etidronate treatment in increasing the lumbar BMD
through the reduction of bone resorption in elderly women
with osteoporosis.
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INTRODUCTION
Osteoporosis is a common health problem in
elderly women. Hormone replacement therapy is
the treatment of choice for the prevention of bone
loss in early postmenopausal women, while bis-
phosphonates are useful agents that increase bone
mineral density (BMD) and subsequently prevent
osteoporotic fractures in elderly women. Bisphos-
phonates such as etidronate and alendronate are
widely used for osteoporosis treatment in Japan.
The efficacy of treatment with cyclical etidronate
(200 mg daily for 2 weeks every 3 months) or
alendronate (5 mg daily) in increasing BMD and
reducing the incidence of osteoporotic fractures in
Japanese patients with osteoporosis has been
clearly demonstrated.
1-3 Both agents are generally
accepted as safe, effective, and well-tolerated
treatments in elderly women with osteoporosis.
These bisphosphonates inhibit osteoclast-medi-
ated bone resorption, and loss of osteoclast func-
tion and apoptosis is the consequence of loss of
function of one or more important signaling pro-
teins. Etidronate can be metabolically incorpor-
ated into nonhydrolyzable analogs of ATP, and
intracellular accumulation of these metabolites
inhibits osteoclast function.
4 A nitrogen-con-
taining bisphosphonate like alendronate is not
metabolized but can inhibit enzymes of the meva-
lonate pathway, thereby preventing the biosyn-
thesis of isoprenoid compounds that are essential
for the post-translational modification of small
GTPases.
4 Thus, the mechanism for the inhibition
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of bone resorption and the subsequent degree of
anti-resorptive effects may differ between etidro-
nate and alendronate.
A meta-analysis study analyzed randomized
controlled trials that reported the efficacy of treat-
ment with etidronate or alendronate for osteo-
porosis, and it suggested that alendronate had a
greater effect on osteoporosis than etidronate.
5
Etidronate and alendronate have also been re-
ported to relieve or prevent back pain in patients
with osteoporosis.
3,6 Some elderly patients with
disabilities and/or back pain can not take alendro-
nate precisely because of its unique method of
taking the medicine. Therefore, it is important to
know how efficacious etidronate treatment is in
elderly women with osteoporosis, in comparison
with alendronate treatment. The relative effective-
ness can be determined only by a head-to-head
comparison in the same population. However, a
direct comparison of the efficacy of treatment with
alendronate and etidronate in Japanese patients
with osteoporosis in a single study has not yet
been reported. The purpose of this open-labeled
prospective study was to compare the effects of
etidronate and alendronate on lumbar BMD, bone
resorption, and back pain in elderly women with
osteoporosis.
MATERIALS AND METHODS
Subjects
Fifty postmenopausal women, 55-86 years of
age, were recruited at our hospital between July
2002 and July 2003. All of them were diagnosed
as having osteoporosis according to the Japanese
criteria.
7,8 According to the Japanese criteria for
osteoporosis in women, patients whose BMD was
< 70% of the young adult mean (YAM) or 70-
80% of the YAM with a history of osteoporotic
fractures were diagnosed as having osteoporosis.
They were divided one by one in the order of
recruiting into two groups with 25 patients in
each group: the cyclical etidronate (200 mg daily
for 2 weeks every 3 months) group and the
alendronate (5 mg/daily) group. These doses are
primary used in Japanese elderly women with
osteoporosis because they are recognized as
being effective doses.
1-3 The duration of treatment
was 12 months. Preliminary screening included
medical history, physical examination, plain
X-ray examination of the thoracic and lumbar
spine, lumbar BMD measurement, blood and
urine biochemical tests, and a questionnaire to
evaluate back pain. The participants who had a
past history of reflux esophagitis, gastric or
duodenal ulcer, or gastrectomy were excluded.
The lumbar BMD was measured, and the assess-
ment of vertebral fractures on plain X-ray films
was performed as described below. The serum
calcium, phosphorus, and alkaline phosphatase
(ALP) levels were measured by using standard
laboratory techniques. The urinary cross-linked
N-terminal telopeptides of type I collagen (NTX)
level was measured by using the enzyme-linked
immunosorbent assay. The assessment of the face
scale score was performed as described below.
None of the subjects suffered from any metabolic
bone disease, and none had a history of hormone
(estrogen) replacement therapy or had ever taken
medication that affects bone metabolism prior to
the present study. All subjects were instructed to
take 800 mg of calcium daily in their food intake
during the study. Informed consent was obtained
from each participant. Table 1 illustrates the
baseline characteristics of the study subjects.
After the start of the treatment, the lumbar BMD,
biochemical markers, and back pain were as-
sessed every 6 months, and plain X-rays of the
thoracic and lumbar spine were assessed at the
end of 12 months of treatment. The primary
endpoints of this study were the lumbar BMD,
urinary NTX level, and back pain. This protocol
was approved by the ethical committee of our
hospital.
Measurement of lumbar BMD
The BMD of the lumbar spine (L1-L4) in the
antero-posterior view was measured by dual en-
ergy X-ray absorptiometry (DXA) using a Hologic
QDR 1500W instrument (Bedford, MA, USA). The
coefficient of variation (100×standard deviation/
mean) of five measurements with repositioning
within 72 hours each time was less than 1.2% in
three persons.Jun Iwamoto, et al.
Yonsei Med J Vol. 46, No. 6, 2005
Assessment of vertebral fractures
Plain lateral X-ray films of the thoracic and
lumbar spine were obtained to find evidence of
vertebral fractures. A vertebral fracture was de-
fined according to vertebral height obtained from
lateral X-ray films based on the Japanese cri-
teria.
7,8 Briefly, the vertebral height was measured
at the anterior (A), central (C), and posterior (P)
parts of the vertebral body, and the presence of
the vertebral fracture was confirmed when (1)
more than a 20 % reduction of vertebral height (A,
C, and P) compared with the neighboring ver-
tebrae was observed; (2) C/A or C/P was less
than 0.8; or (3) A/P was less than 0.75. The assess-
ment of vertebral fractures was performed in the
T4-L4 spine.
Evaluation of back pain
Back pain was evaluated quantitatively by as-
sessing the mood of patients according to the
face scale. The face scale contains ten drawings
of a single face, which is arranged in serial order
by rows, with each face depicting a slightly dif-
ferent mood. Subtle changes in the eyes, eye-
brows, and mouth are used to represent slightly
different levels of mood. They are arranged in
decreasing order of mood and numbered from 1
to 10, with 1 representing the most positive
mood and 10 representing the most negative
mood. As the examiner pointed to the faces, the
following instructions were given to each patient:
"The faces below go from no pain at the top to
severe pain at the bottom. Point to the face that
best shows your current level of back pain."
Thus, facial expression was used as an indicator
of back pain. The validity and reliability of the
face scale have been demonstrated,
9 although
pain is a subjective symptom that is relatively
difficult to evaluate.
Statistical analysis
Data were expressed as the mean ± standard
deviation (SD) in tables and as the mean ±
standard error (SE) in figures. Data were com-
pared between the two groups by using the
unpaired t-test. The significance of longitudinal
changes in the lumbar BMD, face scale score, and
serum ALP and urinary NTX levels and their
longitudinal percent changes was determined by
Table 1. Characteristics of Study Subjects
Etidronate group (n = 25) Alendronate group (n = 25)
Age (yrs)
Height (m)
Body weight (kg)
Body mass index (kg/m
2)
Years since menopause
Lumbar BMD (g/cm
2)
% of the YAM
Number of prevalent vertebral
fractures per patient
Face scale score
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Serum ALP (IU/L)
Urinary NTX (nmol BCE/mmol Cr)
70.7 ± 5.6
1.46 ± 0.05
45.4 ± 6.8
21.2 ± 3.2
21.2 ± 5.3
0.591 ± 0.108
58.3 ± 10.5
2.5 ± 2.7
4.9 ± 1.1
9.3 ± 0.4
3.7 ± 0.7
232 ± 91
67.2 ± 24.4
70.6 ± 8.7
1.46 ± 0.07
45.4 ± 8.4
20.8 ± 3.3
20.6 ± 8.0
0.569 ± 0.107
55.6 ± 10.5
2.4 ± 3.0
4.6 ± 1.2
9.4 ± 0.3
3.4 ± 0.6
243 ± 114
75.8 ± 44.9
Data are expressed as mean ± SD.
BMD, bone mineral density; YAM, young adult mean; ALP, alkaline phosphatase; NTX, cross-linked N-terminal telopeptides of type
I collagen.
There were no significant differences in any parameters between the two groups (by unpaired t-test).Alendronate and Etidronate for Osteoporosis
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using the one-way analysis of variance (ANOVA)
with repeated measurements. Furthermore, lon-
gitudinal percent changes in these parameters
were compared between the two groups by using
the two-way ANOVA with repeated measure-
ments. All statistical analyses were performed
using the Stat View-J5.0 program on a Macintosh
computer. A significance level of p<0.05 was used
for all comparisons.
RESULTS
Changes in lumbar BMD, face scale score, and
biochemical markers
Table 2 shows the longitudinal changes in the
lumbar BMD, face scale score, and biochemical
markers, and Table 3 and Fig. 1 show the longi-
tudinal percent changes in the lumbar BMD, face
scale score, and serum ALP and urinary NTX
levels. The one-way ANOVA with repeated mea-
surements illustrated that the lumbar BMD was
sustained in the etidronate group (2.7% non-sig-
nificant increase) and was increased in the
alendronate group (9.3% significant increase), and
also, it illustrated that the serum ALP and urinary
NTX levels and face scale score decreased in both
groups with no significant changes in the serum
calcium and phosphorus levels. In particular, the
mean reduction in the urinary NTX level at
months 6 and 12 was 13.2% and 38.8%, respec-
tively in the etidronate group and 47.0% and 49.9
%, respectively in the alendronate group. The
two-way ANOVA with repeated measurements
illustrated that longitudinal percent changes in the
lumbar BMD and urinary NTX level significantly
differed between the two groups.
Table 2. Changes in Lumbar BMD, Face Scale Score, and Biochemical Markers
Baseline Month 6 Month 12
p value
One-way ANOVA
Lumbar BMD (g/cm
2)
Etidronate group
Alendronate group
Face scale score
Etidronate group
Alendronate group
Serum calcium (mg/dL)
Etidronate group
Alendronate group
Serum phosphorus (mg/dL)
Etidronate group
Alendronate group
Serum ALP (IU/L)
Etidronate group
Alendronate group
Urinary NTX (nmol BCE/mmol Cr)
Etidronate group
Alendronate group
0.591 ± 0.108
0.569 ± 0.107
4.9 ± 1.1
4.6 ± 1.2
9.3 ± 0.4
9.4 ± 0.3
3.7 ± 0.7
3.4 ± 0.6
232 ± 91
244 ± 114
67.2 ± 24.4
75.8 ± 44.9
0.597 ± 0.112
0.591 ± 0.103
3.8 ± 0.9
3.1 ± 0.4
9.4 ± 0.3
9.4 ± 0.3
3.6 ± 0.6
3.5 ± 0.5
216 ± 63
209 ± 72
55.6 ± 22.8
38.4 ± 25.7
0.609 ± 0.122
0.615 ± 0.096
3.5 ± 1.0
2.8 ± 0.6
9.3 ± 0.4
9.3 ± 0.3
3.6 ± 0.6
3.2 ± 0.6
203 ± 60
189 ± 63
37.8 ± 12.9
32.9 ± 11.0
NS
p<0.001
p<0.0001
p<0.0001
NS
NS
NS
NS
p<0.05
p<0.01
p<0.0001
p<0.0001
Data are expressed as mean ± SD.
One-way analysis of variance (ANOVA) with repeated measurements was used to determine significance of longitudinal change in
parameters. Two-way ANOVA with repeated measurements was used to compare longitudinal changes in parameters between two
groups.
BMD, bone mineral density; ALP, alkaline phosphatase; NTX, cross-linked N-terminal telopeptides of type I collagen.Jun Iwamoto, et al.
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Fig. 1. Percent changes in lumbar BMD, face scale score, and biochemical markers. Data are expressed as mean ± SE.
One-way analysis of variance (ANOVA) with repeated measurements was used to determine significance of longitudinal
percent change in parameters. BMD, bone mineral density; ALP, alkaline phosphatase; NTX, cross-linked N-terminal
telopeptides of type I collagen.
Table 3. Percent Changes in Lumbar BMD, Face Scale Score, Serum ALP, and Urinary NTX
Month 6 Month 12
p value
One-way ANOVA
Two-way ANOVA
(vs Etidronate group)
Lumbar BMD (g/cm
2)
Etidronate group
Alendronate group
Face scale score
Etidronate group
Alendronate group
Serum ALP (IU/L)
Etidronate group
Alendronate group
Urinary NTX (nmol BCE/mmol Cr)
Etidronate group
Alendronate group
1.0 ± 6.3
4.4 ± 7.8
-21.3 ± 18.7
-28.8 ± 17.2
-3.8 ± 14.2
-8.8 ± 20.8
-13.2 ± 30.3
-47.0 ± 20.4
2.7 ± 8.3
9.3 ± 12.2
-26.8 ± 21.7
-36.9 ± 16.0
-7.9 ± 22.3
-13.4 ± 34.5
-38.8 ± 26.9
-49.9 ± 21.9
NS
p<0.001
p<0.0001
p<0.0001
p<0.05
p<0.05
p<0.0001
p<0.0001
p<0.05
NS
NS
p<0.01
Data are expressed as mean ± SD.
One-way analysis of variance (ANOVA) with repeated measurements was used to determine significance of longitudinal percent change
in parameters.
BMD, bone mineral density; ALP, alkaline phosphatase; NTX, cross-linked N-terminal telopeptides of type I collagen.
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Incidence of vertebral fractures
At the end of 12 months, a plain X-ray ex-
amination of the thoracic and lumbar spine re-
vealed no evidence of new thoracic or lumbar
vertebral fractures in any patient of either group.
During the 12 months of treatment, non-vertebral
osteoporotic fractures also did not occur in the
hip, wrist, or shoulder of any patient.
Adverse events
No serious adverse events, such as gastrointesti-
nal tract adverse symptoms caused by reflux
esophagitis or gastric ulcer were observed in any
of the patients. However, minor adverse effects
were observed; thirst, itchy eruption, gastric pain,
and diarrhea were transiently experienced in one
patient in the alendronate group, and itchy erup-
tion and gastric pain were transiently experienced
in one and two patients, respectively in the etidro-
nate group. Because these minor adverse events
were mild and improved within a couple of
weeks, all patients who experienced these side
effects were able to continue taking the medicine.
DISCUSSION
This study showed that etidronate treatment
sustained the lumbar BMD (2.7% non-significant
increase) following a reduction in the urinary
NTX level, while alendronate treatment reduced
the urinary NTX level and increased the lumbar
BMD (9.3% increase). Alendronate treatment had
a greater efficacy than etidronate treatment in
increasing the lumbar BMD in elderly women
with osteoporosis. The percentage increase in the
lumbar BMD after one year of etidronate treat-
ment (200 mg daily for 2 weeks every 3 months)
was reported to be 2.4% in Japanese patients with
involutional osteoporosis.
3 Our non-significant in-
crease in the lumbar BMD might simply be due
to the small sample size.
This difference in the efficacy for the lumbar
BMD may be attributable to these drugs' effect on
bone resorption because the reduction was greater
in the alendronate group (47.0% at month 6 and
49.9% at month 12) than in the etidronate group
(13.2% and 38.8%, respectively). Urinary NTX has
been demonstrated to predict an increase in the
lumbar BMD in response to alendronate treatment
in late postmenopausal women with osteoporosis.
Also, a highly significant correlation has been
demonstrated between the percent decrease in the
urinary NTX level at 3 or 6 months and the
percent increase in the lumbar BMD after 2 years
of alendronate treatment.
10,11 It has also been con-
firmed that a daily dose of 10 mg was more
effective than one of 5 mg in suppressing bone
resorption and increasing the lumbar BMD in
patients with osteoporosis.
12 These results suggest
that when bone resorption is more strongly sup-
pressed, especially in the early period in osteo-
porosis treatment, there is a greater increase in
BMD, which supports our results.
The average age of the participants in this study
was very old. Thus, it was important to compare
the efficacies of etidronate and alendronate with
those of active vitamin D and calcium supplemen-
tation. However, this study lacked the active
vitamin D and calcium group. In Japan, alfacal-
cidol (active vitamin D) had been often used in
the treatment of osteoporosis before bisphos-
phonates, such as etidronate and alendronate
were available. Orimo et al.
13 reported that alfa-
calcidol treatment that was performed for one
year under calcium supplementation (300 mg/
day) sustained the lumbar BMD (only 0.65% in-
crease from the baseline) and reduced the inci-
dence of new vertebral fractures (75/1000 patient
years for alfacalcidol group vs. 277/1000 patient
years for placebo group) in Japanese postmeno-
pausal women with osteoporosis (mean age, 71.9
years). Etidronate and alendronate treatments
seem to be more efficacious than alfacalcidol treat-
ment in increasing the lumbar BMD and pre-
venting new vertebral fractures in Japanese el-
derly women with osteoporosis.
The femoral neck as well as the spine is a clini-
cally important site in the treatment of oste-
oporosis. Therefore, not only should the lumbar
BMD have been assessed but the femoral neck
BMD should have been also. Patients should as-
sume the supine position with the knee and hip
joints flexed at 90 during the lumbar BMD
measurement and with the knee and hip joints
extended during the femoral neck BMD measure-Jun Iwamoto, et al.
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ment. In patients with round back and/or osteo-
arthritis of the knee, who were unable to assume
the proper position especially during the femoral
neck BMD measurement, the measurement was
not assessed precisely. Thus, the femoral neck
BMD could not be assessed in this study.
Spinal osteoporosis causes back pain, possibly
resulting in disabilities in elderly women. The
relief of back pain by intervention is important in
the elderly to improve their activity of daily
living. Since back pain that is associated with
spinal osteoporosis may be linked to increased
bone resorption, drugs affecting bone metabolism
such as bisphosphonates, which are anti-resorp-
tive agents, may be useful for pain control in
elderly women with osteoporosis. In this study,
both treatments with either etidronate or alendro-
nate reduced back pain in elderly women with
osteoporosis.
Nevitt et al.
6 have reported that long-term
alendronate treatment is associated with sig-
nificantly lower risk of patients having days of
bed rest and limited activity due to back pain in
elderly osteoporotic women, which suggests that
alendronate treatment in elderly osteoporotic
patients is efficacious in reducing the burden of
limitation of activity and restriction to bed caused
by back pain. According to the results, alendro-
nate treatment may have the potential not only to
prevent but also to reduce back pain that is asso-
ciated with spinal osteoporosis.
Several reports have demonstrated the effects of
bisphosphonates on bone pain in patients with
bone resorption-related diseases. Short-term treat-
ment with alendronate improved pain, disability,
and standing and walking capacities in patients
with avascular necrosis of the hip, due to the
inhibition of the resorptive action of mature
osteoclasts, an increase in apoptosis of osteoclasts,
and probably a decrease in apoptosis of osteo-
blasts and osteocytes.
14 Intravenous pamidronate
seems to be a valuable treatment for back pain, as
well as in rehabilitating elderly patients who are
suffering from chronic and refractory back pain
caused by osteoporotic vertebral fractures,
15 and
also reduces skeletal pain and biochemical
markers of bone resorption in patients with skele-
tal metastases.
16-18 Furthermore, risedronate de-
creases bone pain in patients with Paget's disease
of bone.
19 These results support our view that
anti-resorptive agents such as bisphosphonates
may have the potential to relieve back pain that
is probably associated with osteoporosis partly
through the suppression of bone resorption.
However, despite the smaller reduction in the
urinary NTX level, etidronate treatment, never-
theless, did improve back pain, similar to alendro-
nate treatment. Thus, other mechanisms might be
involved in the reduction of back (bone) pain
through etidronate treatment in this study. Avail-
able evidence suggests that etidronate treatment
decreases pain by suppressing the production of
interleukin (IL)-6, IL-12, and prostaglandin E2.
20,21
Although etidronate treatment was reported to
transiently reduce metastatic cancer bone pain in
patients with painful bone metastases from pri-
mary cancer sites, a possible explanation for this
relief of metastatic cancer bone pain achieved by
etidronate treatment is speculated to be the com-
bined effects of the suppression of bone resorption
and a reduction in the production of interleukins
and prostaglandins.
17 It is speculated that etidro-
nate might partially reduce back pain by reducing
the production of prostaglandins and cytokines,
22
which might be produced by microfractures re-
sulting from increased bone resorption in the
trabeculae of the spine.
In this study, the increase in the lumbar BMD
and the reduction in the urinary NTX levels were
greater in the alendronate group than in the
etidronate group. It was also reported that with-
out any significant change in the serum 1,25-dihy-
droxyvitamin D3 levels as compared with active
control (alfacalcidol) in patients with osteoporosis,
bisphosphonates such as alendronate decreased
serum osteocalcin levels and increased the serum
PTH levels from the baseline.
1 Thus, comparisons
of other serum chemistry markers such as osteo-
calcin, parathyroid hormone (PTH), 25-hydroxy-
vitmain D3, and 1,25-dihydroxyvitmain D3 would
also be of interest. Further studies are needed to
clarify the differences in these serum chemistry
markers between the etidronate and alendronate
treatments.
There were not cases of drop-out through the
trial due to side effects, personal excuse or non-
compliance in our 50 subjects. Although some side
effects were observed in both groups, they wereAlendronate and Etidronate for Osteoporosis
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mild, and did not result in a single drop-out. This
high compliance might mainly de to the fact (1)
that we adequately explained the reason why bis-
phosphonate treatment was needed based on the
results of thoracic and lumbar spine radiographs
and BMD and bone turnover marker measure-
ments; (2) that we encouraged participants to
continue the trial even though some side effects
were observed, if they were tolerable; and (3) we
excluded the participants who had the past
history of reflux esophagitis, gastric or duodenal
ulcer, or gastrectomy. Thus, the results of this
study may be applicable only to patients without
a past history of problems in the esophagus,
stomach, or duodenum.
There were some notable limitations to the
study. First, this study was not a double-blind
trial but an open-labeled one. Therefore, some
results might possibly be biased. Second, the
number of the study subjects was relatively small
and was not large enough to highlight the
results. Third, because pain is a subjective
symptom, there was difficulty in evaluating back
pain using the face scale score. Moreover, the
change in the face scale score should have been
compared between the bisphosphonate groups
and the placebo group to verify the effect of
bisphosphonates on back pain. Information on
limited activities of daily living due to back pain
other than the face scale score can be helpful in
evaluating the pain relief effect of bisphos-
phonates. Double-blind randomized placebo-con-
trolled studies that are conducted on a sufficient
number of subjects are needed to confirm the
results of this study.
In conclusion, this study showed that in elderly
women with osteoporosis, etidronate treatment
sustained the lumbar BMD following a reduction
in the urinary NTX level and improved back pain,
while alendronate treatment reduced the urinary
NTX level more significantly, resulting in an
increase in the lumbar BMD, and similarly im-
proved back pain. The greater efficacy of alendro-
nate treatment compared to etidronate treatment
in increasing the lumbar BMD by reducing bone
resorption was confirmed by a head-to-head com-
parison in Japanese elderly women with osteo-
porosis.
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